检索结果-内蒙古大学图书馆

7 Phase 3 Trial of an Oral CXCR4 Antagonist, Mavorixafor, for Treatment of Patients With WHIM Syndrome: Preliminary Results From Ongoing Open-Label Extension Period of Continuous Mavorixafor Treatment

引用

Clinical Immunology 2024年 262卷 109949-109949页

作者： Tarrant, Teresa Badolato, Raffaele Donadieu, Jean Dubuc, Susan Hu, Yanping Jiang, Honghua Li, Sunny Steiner, Deborah Yan, Tina Arbet-Engels, Christophe Associate Professor of Medicine Rheumatology and Immunology/Division of Rheumatology and Immunology Department of Medicine Duke University Durham NC USA Full Professor of Pediatrics Chair of Pediatrics ASST Spedali Civili Brescia/Department of Clinical and Experimental Sciences University of Brescia & ASST Spedali Civili Brescia Italy Pediatric Physician/CHU Paris Est - Hôpital d’Enfants Armand-Trousseau Paris France Senior Director Pharmacovigilance & Risk Management/X4 Pharmaceuticals Boston MA USA Director Clinical Research/X4 Pharmaceuticals Boston MA USA Senior Director Biostatistics/X4 Pharmaceuticals Boston MA USA Senior Director Statistical Programming/X4 Pharmaceuticals Boston MA USA Vice President Clinical Development/X4 Pharmaceuticals Boston MA USA Director Statistical Programming/X4 Pharmaceuticals Boston MA USA Chief Medical Officer/X4 Pharmaceuticals Boston MA USA

来源：评论

学校读者我要写书评

暂无评论

POS1050 INCIDENCE RATES OF INTERSTITIAL LUNG DISEASE AMONG PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH ABATACEPT: A POST HOC POOLED ANALYSIS FROM A COMPENDIUM OF CLINICAL TRIALS

引用

Annals of the Rheumatic Diseases 2023年 82卷 843-843页

作者： P. Dieudé J. Sparks A. Fischer L. Chen K. Lozenski S. Dahan M. Chaballa W. Little Paris Cité University Bichat Hospital APHP Department of Rheumatology Paris France Brigham and Women's Hospital Harvard Medical School Division of Rheumatology Inflammation and Immunity Boston United States of America Bristol Myers Squibb Lung Fibrosis Lawrenceville United States of America Syneos Health Biostatistics and Statistical Programming Richmond Canada Bristol Myers Squibb Rheumatology Pipeline and Early Assets Lawrenceville United States of America Bristol Myers Squibb Worldwide Medical Lawrenceville United States of America Bristol Myers Squibb US Medical Immunology and Fibrosis Lawrenceville United States of America Bristol Myers Squibb Worldwide Rheumatology Lawrenceville United States of America

Background Interstitial lung disease (ILD) is a recognized complication of RA. Prior studies have suggested stabilization or improvement of ILD in patients with RA (RA-ILD) treated with abatacept. [1,2] Few studies have evaluated the background incidence rate of RA-ILD. Objectives To determine the incidence rate of clinically significant ILD in a cohort of patients with RA receiving abatacept + MTX versus placebo + MTX from multiple clinical trials. Methods This retrospective analysis examined pooled safety data from ten phase 3 clinical trials of patients with RA treated with background MTX in combination with abatacept or placebo. The term ‘interstitial lung’ was used to identify incidences of ILD reported as AEs in the safety data. The exposure period for each patient was censored at first incidence of clinically significant ILD, 56 days after last study drug administration, or 1 day prior to commencement of another study drug, whichever occurred first. Poisson regression models were used to estimate crude incidence rates per 100 person-years for baseline risk factors within treatment groups, and to estimate incidence rate ratios for the placebo + MTX versus abatacept + MTX treatment groups. Disease activity parameters, DAS28 (CRP) and HAQ-DI, were estimated from baseline to the time of ILD diagnosis (as reported by AEs). Results In total, 3,708 patients (10,521 person-years) treated with abatacept + MTX and 999 patients (938 person-years) treated with placebo + MTX were included. Patients treated with placebo + MTX had a higher incidence rate of ILD per 100 person-years (95% CI) versus those treated with abatacept + MTX (0.43 [0.16–1.14] vs 0.10 [0.05–0.18], respectively; Figure 1). The incidence rate ratio of placebo + MTX versus abatacept + MTX treatment groups for the total population was 4.49 (95% CI, 1.23–13.42). For all subpopulations stratified by baseline risk factors (where ≥ 1 patient in each treatment group had an ILD event), incidence rate ratios wer

关键词：

来源：评论

学校读者我要写书评

暂无评论

1736 – Long-acting injectable risperidone and oral antipsychotics in patients with schizophrenia - a prospective one-year non-interventional study (inors)

引用

European Psychiatry 2013年第S1期28卷 1-1页

作者： Schreiner, A. Svensson, A. Wapenaar, R. Cherubin, P. Princet, P. Serazetdinova, L. Starostina, N. Zink, M. EMEA Medical Affairs Janssen-Cilag Medical Affairs EMEA Neuss Germany EMEA Medical Affairs Janssen-Cilag AB Sollentuna Sweden Biostatistics & Programming Janssen Cilag B.V. Tilburg The Netherlands EMEA Medical Affairs Janssen Cilag France Issy-les-Moulineaux Centre Hospitalier Spéchialisé de Fains-Véel Fains-Véel France Federal Institution of Healthcare Psychoneurologic Dispensary No.5 Saint Petersburg Federal Institution of Healthcare Psychiatric Hospital No.2 Nizhni Novgorod Russia Zentralinstitut für Seelische Gesundheit Klinik für Psychiatrie und Psychotherapie Mannheim Germany

Introduction and objectives To explore safety, tolerability, treatment response and hospitalizations in adult patients with schizophrenia treated with long-acting injectable risperidone (RLAI) or oral antipsychotic standard of care (oAP) in routine clinical practice. Methods Prospective one-year open-label non-interventional study exploring flexible doses of RLAI and oAPs. Primary outcome was the number of hospitalizations from baseline to endpoint. Additional outcomes were changes in the Clinical Global Impression of Schizophrenia (CGI-SCH), patient functioning (Global Assessment of Functioning) and treatmentemergent adverse events (TEAEs). Results The intent-to-treat analysis included 561 patients on RLAI and 522 patients on oAPs (44% female gender, mean age (±SD) 42.2±13.1 years). Demographics and baseline characteristics were comparable, yet RLAI-treated patients had higher disease severity, lower baseline functioning and more substance abuse. The number of hospitalizations did not differ between the two groups while median duration of hospitalization was significantly shorter with RLAI (12.3 vs 20.6 days). Positive, negative, cognitive symptoms, disease severity, patient functioning and medication satisfaction improved significantly better with RLAI than oAPs. The most frequently reported TEAEs (=2% in any group) for RLAI and oral APs were increase of body weight (5.0%; 5.6%), psychotic disorder (2.7%; 4.0%), schizophrenia (2.5%; 3.1%), anxiety (2.3%; 2.7%), insomnia (0.9%; 3.1%) and somnolence (0.4%; 2.5%), respectively. Conclusion This one-year non-interventional study supports results of recent randomized controlled trials that treatment with RLAI is associated with less days spent in hospital, better symptomatic and functional outcomes and higher patient satisfaction with medication compared to oral APs.

关键词：

来源：评论

学校读者我要写书评

暂无评论

VP6-2022: Adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years' follow-up

引用

Annals of Oncology 2022年第9期33卷 986-987页

作者： S. Loibl J. Jassem A. Sonnenblick D. Parlier E. Winer J. Bergh R.D. Gelber E. Restuccia Y-H. Im C. Huang F. Dalenc I. Calvo M. Procter C. Caballero E. Clark H.L. Gomez Moreno J. Bliss G. Viale J. Bines M. Piccart Medicine and Research Dept. German Breast Group (GBG) Forschungs GmbH Neu-Isenburg Germany Oncology & Radiotherapy Medical University of Gdansk Gdansk Poland Oncology Department Tel Aviv Sourasky Medical Center-(Ichilov) Tel Aviv Israel Clinical Trials Support Unit Institut Jules Bordet Brussels Belgium Yale Cancer Center Yale University School of Medicine - Yale Cancer Center New Haven CT USA Department of Oncology-Pathology Karolinska Institutet and Breast Cancer Centre Cancer Theme Karolinska University Hospital Stockholm Sweden Biostatistics Dana Farber Cancer Institute Boston MA USA Product Development Oncology F. Hoffmann-La Roche Ltd Basel Switzerland Medicine Dept. Hematology/Medical Oncology Division Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine Seoul Republic of Korea Surgery Dept. NTUH - National Taiwan University Hospital Taipei Taiwan Oncologie 1A Institut Universitaire du Cancer Toulouse - Oncopole Toulouse France Breast Cancer Unit MD Anderson Cancer Center Madrid Madrid Spain Statistics and Programming Frontier Science Scotland Kincraig UK Medical Department Breast International Group (BIG) - AISBL Brussels Belgium Data Sciences - Data & Statistical Sciences (DSS) Roche Products Limited Welwyn Garden City UK Medicine Department INEN - Instituto Nacional de Enfermedades Neoplasicas Lima Peru Clinical Trials and Statistics Unit ICR - Institute of Cancer Research London UK Department of Oncology Università degli Studi di Milano Milan Italy Medical Oncology Department Instituto Nacional de Cancer - Research Center Rio de Janeiro Brazil Institut Jules Bordet Brussels Belgium

来源：评论

学校读者我要写书评

暂无评论

277MO SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), in ER+/ HER2- metastatic breast cancer (mBC): Biomarker analyses from a phase I/II study

引用

Annals of Oncology 2020年 31卷 S351-S351页

作者： S. Chandarlapaty A. Bardia S. Lord H. Linden V. Pelekanou N. Ternes J. Ming V. Boutet E. Boitier A. Gosselin J. Sang Lee W. Dos-Santos Bele A. Protopopov M. Celanovic A-L. Bauchet M. Campone Medicine Memorial Sloan Kettering Cancer Center New York NY USA Medical Oncology Massachusetts General Hospital Harvard Medical School Boston MA USA Department of Oncology University of Oxford Churchill Hospital Oxford UK Department of Medicine University of Washington Medical Center Seattle WA USA Clinical Precision Oncology-Tranlsational Medicine Early Development Sanofi Cambridge MA USA Biostatistics and Programming Sanofi Paris France Oncology Sanofi Bridgewater NJ USA TMED & Biomarkers & Clinical Bioanalyses Sanofi Paris France Precision Oncology Sanofi Cambridge MA USA Molecular Profiling Precision Oncology Sanofi Paris France Oncology-OMD Sanofi Cambridge MA USA Medical Oncology Institut de Cancérologie de l'Ouest Saint-Herblain France

来源：评论

学校读者我要写书评

暂无评论

EFFICACY AND SAFETY OF EXPERIMENTAL CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS VERSUS AXICABTAGENE CILOLEUCEL (YESCARTA) FOR THE TREATMENT OF RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA: MATCHING ADJUSTED INDIRECT COMPARISONS AND SYSTEMATIC REVIEW

引用

Hematology, Transfusion and Cell Therapy 2021年 43卷 S256-S256页

作者： B Weinstein B Muresan S Solano AV Macedo Y Lee Y Su Y Ahn C Camargo G Kim D Carpenter Department of Environmental Health Sciences School of Public Health University at Albany Rensselaer United Kingdom Health Sciences Unit University of Groningen University Medical Center Groningen Groningen The Netherlands Principles and Practice of Clinical Research (PPCR) Program ECPE Harvard T.H. Chan School of Public Health Boston United Kingdom Hematology Clinic Hospital da Polícia Militar Belo Horizonte MG Brazil Department of Pharmaceutical Sciences School of Pharmacy Texas Tech University Health Sciences Center Amarillo United Kingdom Inari Medical Biostatistics and Programming Department Irvine United Kingdom Department of Plastic Surgery Faculdade de Medicina Universidade de São Paulo (FMUSP) São Paulo SP Brazil Institute of Experimental and Clinical Pharmacology and Toxicology Faculty of Medicine University of Freiburg Freiburg Germany Institute for Health and the Environment University at Albany Rensselaer United Kingdom

Introduction Despite the high response rates seen with Chimeric Antigen Receptor (CAR) T-cell therapy for relapsed/refractory Large B-cell lymphoma (R/R LBCL), post-therapy relapse remains a key challenge. To date, no study has evaluated the comparative efficacy and safety of experimental CAR T-cell products versus currently approved CAR T-cell therapies. Objective To indirectly compare the efficacy and safety of novel, experimental CAR T-cell products against the first FDA-approved CAR T-cell construct, Axicabtagene ciloleucel (Yescarta). Methods In compliance with the PRISMA guidelines, we performed a systematic review, which identified 16 independent, early-phase clinical trials consisting of 193 LBCL patients with individual patient data (IPD). We categorized eight pooled populations based on the target antigens (CD19, CD20), co-stimulatory domains (CD28, 4-1BB), and CAR T-cells administered with or without concomitant autologous stem cell transplant (ASCT). The pooled populations were categorized as follows: (1) dual targeting strategies, such as tandem ***20, n = 28; (2) co-infusion of CD19 and CD20 CARs, n = 21; (3) third-generation CARs, n = 26; (4) CD19 CARs with modified constructs for reduced toxicity, including ***.86, n = 21; and (5) ***828Z, n = 14; (6) CD19. 4-1BB.S manufactured in China, n = 24; (7) concomitant ASCT and ***28, n = 45; and (8) CD20 CARs with a 4-1BB co-stimulatory domain, n = 14. A Matching Adjusted Indirect Comparison (MAIC) statistical technique was applied to account for heterogeneity in the study population across trials. Estimates for the experimental CAR T-cell trials were adjusted using patient-level data to match the ZUMA-1 (Yescarta, n = 108) study population based on mutually reported key baseline covariates, including age, disease stage, histology, refractoriness, number of prior lines of therapy, and extranodal disease. The study endpoints for this study included progression-free survival (PFS), cytokine r

关键词：

来源：评论

学校读者我要写书评

暂无评论

1098P Mechanisms of recurrence following mRNA-4157 (V940) plus pembrolizumab or pembrolizumab alone in resected melanoma from the mRNA-4157-P201 (KEYNOTE-942) trial

引用

Annals of Oncology 2024年 35卷 S727-S728页

作者： R.J. Sullivan M. Lu S. Koppolu J.S. Weber M.S. Carlino M.A. Khattak G. Ansstas M.H. Taylor M. Mckean G.V. Long M.B. Faries J.J. Luke V. Sehgal A. Rao H. Mao J. Guo M. Brown R. Meehan I. Feldman L. Srinivasan Medical Oncology/Hematology MGH - Massachusetts General Hospital Boston MA USA Translational Medicine Moderna Inc. - Global Headquarters Cambridge MA USA Computational Science Moderna Inc. - Global Headquarters Cambridge MA USA Laura and Isaac Perlmutter Cancer Center NYU Langone Health New York NY USA Medical Oncology Melanoma Institute Australia and Westmead Hospital Sydney NSW Australia Oncology Hollywood Private Hospital and Edith Cowan University Perth WA Australia Oncology Washington University School of Medicine St. Louis MO USA Medical Oncology Earle A. Chiles Research Institute Portland OR USA Oncology Sarah Cannon Research Institute - Cancer Centre Nashville TN USA Melanoma Institute Australia The University of Sydney Royal North Shore and Mater Hospitals Sydney NSW Australia Surgical Oncology The Angeles Clinic and Research Institute a Cedars-Sinai affiliate Los Angeles CA USA Medicine - Hematology/Oncology UPMC Hillman Cancer Center and University of Pittsburgh Pittsburgh PA USA Biometrics Moderna Inc. - Global Headquarters Cambridge MA USA Clinical biomarkers Moderna Inc. - Global Headquarters Cambridge MA USA Biostatistics Moderna Inc. - Global Headquarters Cambridge MA USA Biostatistics & Programming Moderna Inc. - Global Headquarters Cambridge MA USA Clinical Development Moderna Inc. - Global Headquarters Cambridge MA USA Oncology Moderna Inc. - Global Headquarters Cambridge MA USA

来源：评论

学校读者我要写书评

暂无评论

1411P Tusamitamab ravtansine plus ramucirumab as 2L therapy or beyond in patients with metastatic NSq NSCLC and high CEACAM5 expression (CARMEN-LC04)

引用

Annals of Oncology 2023年 34卷 S807-S807页

作者： G.K. Dy B.C. Cho J. Oliveira M.D. Isla Casado A. Blasco Cordellat M. Zemanova J. Roubec L. Vila Martinez L. Charbonnier C. Soufflet J. de Castro Carpeño Department of Medicine Roswell Park Comprehensive Cancer Center Buffalo NY USA Division of Medical Oncology Yonsei Cancer Center Yonsei University College of Medicine Seoul Republic of Korea Medical Oncology Service Early Phase Clinical Trial Unit-IPO Porto/RISE@CI-IPOP (Health Research Network Experimental Pathology and Therapeutics Group Research Center (CI-IPOP)/RISE@CI-IPOP (Health Research Network) Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Porto Portugal Medical Oncology Department Hospital Clínico Universitario Lozano Blesa Zaragoza Spain Medical Oncology Department Hospital General de Valencia Valencia Spain Department of Oncology First Faculty of Medicine Charles University and General University Hospital in Prague Prague Czech Republic Pneumooncology Nemocnice AGEL Ostrava-Vítkovice Ostrava-Vítkovice Czech Republic Oncology Department Consorci Corporació Sanitària Parc Taulí de Sabadell Sabadell Spain Biostatistics & Programming Sanofi Chilly-Mazarin France Clinical Development Sanofi Vitry-sur-Seine France Medical Oncology Service Hospital Universitario La Paz Madrid Spain

来源：评论

学校读者我要写书评

暂无评论

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

请选择保存的检索档案：

请选择收藏分类：

通借通还

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：